검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Belzutifan |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma, Renal Cell |
Overview Indication | Carcinoma, Renal Cell |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeting these pathways are often limited by asynchronous drug decay and adaptive signaling |
MoA Biomarker | PD-L1 expression |
PK/PD Half-life | 38 h |
PK/PD Species | Rat, Human, Discovery of NKT2152, a Potent and Selective HIF-2α |
PK/PD Animal (cat.) | Human, Rat, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat, Human, Discovery of NKT2152, a Potent and Selective HIF-2α |
Toxicology Animal (cat.) | Human, Rat, In vitro |
Toxicology Major finding | Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.. Adjuvant pembrolizumab improves disease-free and overall survival among patients with resected clear-cell renal-cell carcinoma. The hypoxia-inducible factor 2α inhibitor belzutifan has activity in advanced disease. Adjuvant pembrolizumab with belzutifan may further improve outcomes in patients with clear-cell renal-cell carcin… |
Clinical Primary efficacy | ORR 21.9% |
Clinical ORR | 21.9% |
Clinical Result source | ClinicalTrials.gov NCT04195750 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Belzutifan |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma, Renal Cell |
Overview Indication | Carcinoma, Renal Cell |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeting these pathways are often limited by asynchronous drug decay and adaptive signaling |
MoA Biomarker | PD-L1 expression |
PK/PD Half-life | 38 h |
PK/PD Species | Rat, Human, Discovery of NKT2152, a Potent and Selective HIF-2α |
PK/PD Animal (cat.) | Human, Rat, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat, Human, Discovery of NKT2152, a Potent and Selective HIF-2α |
Toxicology Animal (cat.) | Human, Rat, In vitro |
Toxicology Major finding | Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.. Adjuvant pembrolizumab improves disease-free and overall survival among patients with resected clear-cell renal-cell carcinoma. The hypoxia-inducible factor 2α inhibitor belzutifan has activity in advanced disease. Adjuvant pembrolizumab with belzutifan may further improve outcomes in patients with clear-cell renal-cell carcin… |
Clinical Primary efficacy | ORR 21.9% |
Clinical ORR | 21.9% |
Clinical Result source | ClinicalTrials.gov NCT04195750 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교